

***Media Coverage on Avesthagen Press Release
(AVENTTM)***

S.NO	ARTICLE	PUBLICATION
1	Avesthagen arthritis drug trial	Financial Express
2	Avesthagen Drug completes trial	Financial Chronicle
3	Avesthagen arthritis drug trial	Financialexpress.com
4	Avesthagen completes pre-clinical trial of new arthritis drug	Business-standard.com
5	Avesthagen moves towards clinicals of its biosimilar AVENT TM	Techwhack.com



PUBLICATION	THE FINANCIAL EXPRESS
EDITION	BANGALORE
DATE	03-06-2010
PAGE NO	05

Avesthagen arthritis drug trial

Biotech firm Avesthagen on Wednesday announced the successful completion of the pre-clinical efficacy trial for one of its biosimilar drugs for treating rheumatoid arthritis, Avent. The results indicate that Avent developed by Avesthagen is effective in addressing arthritic conditions, the company claimed in a press release. Global sales of the commercially available reference drug were around \$6.58 billion in 2009.

[TOP](#)



PUBLICATION	FINANCIAL CHRONICLE
EDITION	BANGALORE
DATE	03-06-2010
PAGE NO	06

Avesthagen drug completes trial

Avesthagen on Wednesday announced the successful completion of the pre-clinical efficacy trial for one of its biosimilar drugs for treating rheumatoid arthritis, Avent.

TOP

- [City Newslines](#)
- [Express Cricket](#)
- [Loksatta](#)
- [Express Computer](#)
- [Exims](#)

[FE Home](#)- [Back Page](#) - Story

Quick View

fe Bureaus

Posted: Thursday, Jun 03, 2010 at 2307 hrs IST

Updated: Thursday, Jun 03, 2010 at 2307 hrs IST



Font Size



[Print](#)



[Feedback](#)



[Email](#)



[Discuss](#)

- [Cold Coin](#)
- [Flower & Cake Delivery](#)
- [Coffee Maker](#)
- [Laughing Buddha \(Gold\)](#)

: GE Appliances forays into India

Announcing its entry into the Indian market with the launch of air conditioners in Punjab, GE Appliances said that it would soon roll out other kinds of home appliances to earn a revenue of up to \$10 million by the end of the current fiscal. GE appliances has tied up with Delhi-based Shelka Marketing for distributing appliances in the North.

Avesthagen arthritis drug trial

Biotech firm Avesthagen on Wednesday announced the successful completion of the pre-clinical efficacy trial for one of its biosimilar drugs for treating rheumatoid arthritis, Avent. The results indicate that Avent developed by Avesthagen is effective in addressing arthritic conditions, the company claimed in a press release. Global sales of the commercially available reference drug were around \$6.58 billion in 2009.

Panasonic bets big on World Cup

Cashing in on the football mania during the FIFA world Cup, Panasonic India, the largest manufacturers of electronic products, is targeting sales turnover of Rs 75 crore from soccer crazy states of Kerala, West Bengal and the Union Territory of Goa.

Usher Agro eyes Rs 1k-cr turnover

Rice processor Usher Group on Wednesday said that its turnover is likely to jump three-fold to Rs 1,000 crore in the next two years, on increased capacity. The company, a listed entity, has two rice processing mills at Mathura and one at Buxar in Bihar with a total capacity of 2.5 lakh tonne.

More from [Back Page](#)

[Show dividends in Rs, not percentage, Sebi tells MFs](#)[Regulator keen to improve exchange-traded volumes](#)[Mkts touch 3-wk high on global cues](#)[High-frequency trade charges at NSE pared](#)[I-T dept files caveat against Vodafone in Bombay HC](#)[Quick View](#)[ARSS Infra bags Rs 51-cr order in Orissa](#)

Discuss this story on [expressindia forums](#)

Post Comments

[TOP](#)

Comments: (Limit 3,000 characters)

Name

Message



"We IMPROVE.
your business operations with a 360-degree view of your customers...

Rollover to know more



Sign Up For a TRADING ACCOUNT

Business Standard

Friday, Jun 04, 2010

Welcome, **Guest**
[Login](#) | [Register](#)

[Advanced Search](#)
[Feedback](#) | [RSS](#)
[Content Guide](#)
Follow us on [twitter](#) [f](#)

Home | Markets & Investing | **Companies & Industry** | Banking & Finance | Economy & Policy | Opinion | Life & Leisure | Mgmt & Mktg | Tech World | BS Products

Section Home | [News Now](#) | [Today's Paper](#) | [Q&A](#) | [People in the News](#) | [Industry News](#) | [Features](#) | [The Compass](#) | [Research & Analysis](#) | [Opinion](#) | [Corporate Results](#)

Home > [Companies & Industry](#) | [Live Markets](#) | [Smart Portfolios II](#) | [Commodities](#) | Search: Keyword POWERED BY Google

Avesthagen completes pre-clinical trial of new arthritis drug

Press Trust of India / Bangalore June 2, 2010, 16:41 IST

Leading biotech firm Avesthagen today announced the successful completion of the pre-clinical efficacy trial for one of its biosimilar drugs for treating rheumatoid arthritis, Avent.

The results indicate that Avent developed by Avesthagen is effective in addressing arthritic conditions, the company claimed in a press release here today. The global sales of the commercially available reference drug were around \$ 6.58 billion in 2009.

Avent is the biosimilar version of a fully humanised soluble tumor necrosis factor receptor and can be used to reduce signs and symptoms in patients with moderate-to-severe rheumatoid arthritis, ankylosing spondylitis, plaque psoriasis, psoriatic arthritis and juvenile idiopathic arthritis.

Its trials on mice have showed that Avent is effective in preventing the arthritic pathology developing in the transgenic mice when compared to control mice.

According to company chairman Villoo Morawala Patell, "Avesthagen is making progress in its biosimilars programme as per schedule to provide cost-effective healthcare solutions."

Also Read

[Related Stories](#) | [News Now](#)

- Avesthagen to revisit IPO plans
- Avesthagen forms JV with French co-operative group
- Avesthagen to rope in JV partner for its SBU
- Avesthagen ties up with Chilean biotech firm
- ITC raises stake in Leela to 10%
- Leela to raise Rs 750 cr through QIP, FCCB

TOP

Other Stories

- A range bound market
- ANALYSIS: Niche cloud computing firms in M&A spotlight
- Boeing aims to boost international defense sales
- 'IMF needs more funds after supporting Greece bailout'
- Doubts over global economy resurface as G20 gathers

More

Tags : Avesthagen | biosimilar drugs | rheumatoid arthritis | Avent

Read Business news in [हिंदी](#)

Advertisements

- [Wake up it's time to put your health first - click to know more](#)
- [Software Company Uses CRM Solution to Manage Sales Activities](#)
- [A Health Insurance Policy with a difference - click to know more](#)
- [Find the right solutions and become a smarter medium-sized business](#)
- [Reduce cost and increase profitability.. know more](#)
- [Overcome IT challenges & exceed business expectations with a simple click](#)
- [GiftwithLove.com: Flowers/ Cake/Gift: Same Day Delivery in India](#)

Introducing 

Share this Story »

[Print this](#)

[Email this](#)

[Add to favorites](#)

[Twitter](#)

[Google Buzz](#)

[del.icio.us](#)

[digg](#)

[newsVine](#)


[Reddit](#)

[Facebook](#)

Discussion Board / User Comments (0)

Display Name Email-Id

Post your comment



Most Popular

[Read](#) | [E-Mailed](#) | [Commented](#)

- **Madhukar Sabnavis:** Passion of a creator 'Phet' Oman-bound; may hit Pakistan, Gujarat by weekend
- GTL Infra, Essar in race for Aircel tower assets
- R-Power puts Maharashtra gas-based unit on fast track
- Cyclone 'Phet' moves towards Oman coast

More



BS Poll

[Cast Your Vote](#)

AVESTHAGEN moves towards Clinicals of its biosimilar AVENT™

June 3rd, 2010 [Leave a comment](#) Visited 15 times, 7 so far today

New Delhi. June 3, 2010: AVESTHAGEN announced that it has successfully completed the pre-Clinical efficacy trial for one of its biosimilar drugs AVENT™ at Biomedcode Hellas S.A. The results indicate that AVENT™ developed by Avesthagen is effective in addressing arthritic conditions. The global sales of the commercially available reference drug were around \$ 6.58 billion in 2009.

AVENT™ is the biosimilar version of a fully humanized soluble tumor necrosis factor (TNF) receptor. AVENT™ is indicated for reducing signs and symptoms, in patients with moderate to severe Rheumatoid Arthritis, ankylosing spondylitis, plaque psoriasis, psoriatic arthritis and Juvenile Idiopathic Arthritis.

Pre-Clinical Efficacy of AVENT™ was carried out in a USFDA accredited human TNF transgenic murine model for Rheumatoid Arthritis. In these mice, the human TNF α gene is over-expressed which results in a progressive arthritic phenotype that is similar to that observed in humans. The results show that Avesthagen's biosimilar AVENT™ was effective in preventing the arthritic pathology developing in the transgenic mice when compared to control mice. Marked improvement was also evident in the group of mice treated with AVENT™ in comparison to control group of mice, in all scores measured, namely statistically significant arthritis inhibition of ~60% in histopathology and ~80% with in-life clinical measurements.

Avesthagen has successfully developed a proprietary expression vector technology pAVGEN™ to generate high protein yielding mammalian cell lines. The AVENT™ cell line have been developed using this proprietary technology. This product is currently being scaled up for Clinical Trials at Inno Biologics facility in Malaysia.

The bioPharmaceutical division at Avesthagen has developed a pipeline of biosimilars using mammalian expression systems, four of which have been granted regulatory approval by the RCGM for initiating pre-clinical toxicity and efficacy studies. Avesthagen's biosimilars address a wide range of areas including autoimmune disease, cancer, sepsis, anemia, cardiovascular disorders and bone health. At present four molecules are in advanced stage of development. Avesthagen has initiated the manufacture of its biosimilars in Malaysia for clinical studies.

According to Dr. Viloo Morawala Patell, CMD, Avesthagen Limited, "Avesthagen is making progress in its biosimilars program as per schedule to provide cost effective healthcare solutions."

About Avesthagen:

Continues on next page...

Continues...

AVESTHAGEN LIMITED (www.avesthagen.com) is an integrated systems biology platform company that focuses on achieving convergence of food, pharma and population genetics leading to predictive preventive and personalized healthcare. It employs 400 people worldwide and is headquartered in Bangalore. It began business operations in 2001. Since its inception Avesthagen has grown into one of India's innovative biotech companies that in addition to its agri-biotechnologies product pipeline has developed scientifically validated botanical bioActives derived from Indian medicinal plants. Avesthagen has developed a pipeline of bio-similar drugs. Avesthagen Limited has four strategic business units: bioPharmaceuticals, bioNutrition, bioAgriculture and Science & Innovation and collaborates at every stage in the value chain with appropriate partners, both public and private.

For more information, please contact:

Anil Chauhan

SVP (Operations), Avesthagen Limited

Tel: +91 870 28411665 ext. 5073

Email: [anilram {at} avesthagen\(.\)com](mailto:anilram@avesthagen.com)

TOP